Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

March 1, 2024

Study Completion Date

September 30, 2025

Conditions
Ovarian Cancer
Interventions
DRUG

Bevacizumab

Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.

DRUG

Olaparib

Olaparib dosing is oral at 300 mg twice daily

Trial Locations (1)

Unknown

RECRUITING

Vall d'Hebron Institute of Oncology, Barcelona

All Listed Sponsors
lead

Vall d'Hebron Institute of Oncology

OTHER